Morningstar

H. Lundbeck AS Ordinary Shares - Class B HLUN B

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 43.68 +0.38 (0.88%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

No-Moat Lundbeck's Strategic Brands Drive Sales, but Loss of Exclusivity Weighs on Long-Term Outlook

Rachel Elfman

Lundbeck's portfolio focuses on central nervous system drugs, including antidepressants, antipsychotics, and antiepileptic products. While incremental innovations and label expansions helped Lundbeck earn excess returns over the past several years, this occurred before many of Lundbeck’s patents expired. Since then, generic entry has created significant competition and pricing pressure for the firm.

Read Analysis

Price vs Fair Value

View History
HLUN B is trading at a LOCK|&spD$% premium.
Price
DKK 43.30
Fair Value
LOCK|.y
Uncertainty
LOCK|$%
1-Star Price
LOCK|.@j%
5-Star Price
LOCK|.v
Economic Moat
LOCK|>?
Capital Allocation
LOCK|!&sFdv

Bulls Say, Bears Say

Bulls

Vyepti received FDA approval in 2020 and EU approval in 2022, and it has had strong uptake globally.

Bears

Due to the complex nature of CNS disorders and the high frequency of placebo responses, which can confound trial results, the development process has been filled with obstacles.

Show More

Trading Information

Previous Close Price
DKK 43.30
Day Range
DKK 42.90–43.78
52-Week Range
DKK 36.34–47.78
Bid/Ask
DKK 43.46 / DKK 43.60
Shares Outstanding
992.40M
Market Cap
DKK 43.35B
Volume/Avg
429,249 / 569,227

Key Statistics

Price/Earnings (Normalized)
6.68
Price/Sales
1.65
Dividend Yield (Trailing)
2.66%
Dividend Yield (Forward)
2.66%
Dividend Payment Schedule
Mar
Total Yield
2.70%

Company Profile

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
5,000
Website
https://www.lundbeck.com

Competitors

Valuation

View More
Metric
HLUN B
ALNY
Price/Earnings (Normalized)
 6.6828.86
Price/Book Value
 1.6022.83
Price/Sales
 1.656.68
Price/Cash Flow
 6.8921.53
Price/Earnings
HLUN B
ALNY

Financial Strength

Metric
HLUN B
ALNY
Quick Ratio
 0.902.79
Current Ratio
 1.373.05
Interest Coverage
 —3.12
Quick Ratio
HLUN B
ALNY

Profitability

Metric
HLUN B
ALNY
Return on Assets (Normalized)
 11.52%22.09%
Return on Equity (Normalized)
 23.81%149.53%
Return on Invested Capital (Normalized)
 15.97%63.06%
Return on Assets
HLUN B
ALNY

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|<wG^^p&LOCK|wC@F$66B
 Teva Pharmaceutical Industries Ltd
TEVA
LOCK|d??zs>XLOCK|yv??$46B
 Haleon PLC ADR
HLN
LOCK|>y<q@dLOCK|^fb$38B
 Zoetis Inc Class A
ZTS
LOCK|^l&T<YRVLOCK|@l$29B
 Viatris Inc
VTRS
LOCK|^xjdy?LOCK|LS$20B
 Elanco Animal Health Inc
ELAN
LOCK|%^LOCK|Z%$11B
 Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|%&DW!yLOCK|^W$10B
 Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|<!Cw!>LOCK|RW>$7B
 Prestige Consumer Healthcare Inc
PBH
LOCK|Jb>%V%gLOCK|HBNpf$2B
 Perrigo Co PLC
PRGO
LOCK|SsX^?PLOCK|YS$2B

Sponsor Center